Biotec plans for w/w launch of 2-day MDR-TB test
This article was originally published in Clinica
The prospects for treating multi-drug resistant tuberculosis (MDR-TB) in the world's most acutely affected countries received a boost this week with the launch of Biotec Laboratories' rapid new test. The test is now available in Europe's private sector, but the firm has plans to launch it into the public domain of developing countries. The firm claims that its "FASTPlaque-Response" test takes just two days to complete, while current testing methods can take months to produce results.